QR-010

January 14, 2019January 21, 2019

Eluforsen Improves CFTR Protein Function in CF Patients with F508del Mutations, Phase 1 Trial Shows

cystic fibrosis, News

An exploratory Phase 1 trial showed that repeated intranasal treatment with the therapy eluforsen improved CFTR protein activity in adults with cystic fibrosis (CF) carrying F508del mutations in both ... Read more

January 12, 2018January 12, 2018

ProQR and Galapagos Collaborating on a New Way of Developing Fibrosis Treatments

cystic fibrosis, News

ProQR Therapeutics and Galapagos are working together on a new approach to treating the tissue scarring seen in cystic fibrosis. The collaboration will take advantage of ProQR’s proprietary next-generation RNA ... Read more

November 1, 2017November 1, 2017

#NACFC2017 – Cystic Fibrosis Experts from 46 Countries Gathering in Indianapolis for NACFC Convention

cystic fibrosis, News

About 4,400 researchers, doctors, patients and others from 46 countries are converging on Indianapolis for the 31st Annual North American Cystic Fibrosis Conference — the world’s largest gathering dedicated to cystic ... Read more

September 28, 2017September 28, 2017

ProQR’s Inhaled RNA Therapy Improves CF Symptoms in Phase 1 Clinical Trial

News

ProQR Therapeutics says its investigational drug QR-010 improved respiratory symptoms in 70 adults with cystic fibrosis (CF) who participated in a Phase 1b trial of the inhaled therapy. Researchers saw the ... Read more

August 31, 2017August 31, 2017

ProQR Completes Phase 1b Trial of Inhaled Therapy for CF Patients with F508del CFTR Mutation

cystic fibrosis, News

ProQR Therapeutics has finished a dose-escalating Phase 1b clinical trial evaluating the safety, stability and distribution throughout the body of its investigational therapy QR-010 in cystic fibrosis (CF) patients with a confirmed F508del ... Read more

April 5, 2017April 5, 2017

ProQR’s Cystic Fibrosis Therapy QR-010 Now Protected by U.S., European Patents Until 2033

cystic fibrosis, News

Dutch pharmaceutical company ProQR Therapeutics now has two key patents protecting its first-in-class ribonucleic acid (RNA)-based oligonucleotide QR-010 for the treatment of cystic fibrosis (CF) in the United States and Europe. The patents ... Read more

April 3, 2017April 3, 2017

Cystic Fibrosis-related ProQR Names New Therapy Development Chief

cystic fibrosis, News

David M. Rodman is the new chief development strategy officer at ProQR Therapeutics, a leader in RNA therapies for cystic fibrosis (CF) and other diseases. Rodman, a medical doctor, will ... Read more

January 4, 2017January 4, 2017

Therapy Targeting CF Mutation Appears to Restore CFTR Gene in Homozygous Patients in Study

News

ProQR Therapeutics is reporting that an early clinical study of QR-010 in cystic fibrosis patients homozygous for the ΔF508 mutation in the CFTR gene met its primary endpoint. After four weeks of treatment, these ... Read more

August 23, 2016August 23, 2016

Data on Inhaled CF Therapy in Clinical Testing To Be Presented at NACFC 2016

News

ProQR Therapeutics announced that it plans to announce proof-of-concept results from tests of its lead candidate to treat cystic fibrosis (CF), QR-010, at a scientific conference this year, and is continuing ... Read more

QR-010

Eluforsen Improves CFTR Protein Function in CF Patients with F508del Mutations, Phase 1 Trial Shows

ProQR and Galapagos Collaborating on a New Way of Developing Fibrosis Treatments

#NACFC2017 – Cystic Fibrosis Experts from 46 Countries Gathering in Indianapolis for NACFC Convention

ProQR’s Inhaled RNA Therapy Improves CF Symptoms in Phase 1 Clinical Trial

ProQR Completes Phase 1b Trial of Inhaled Therapy for CF Patients with F508del CFTR Mutation

ProQR’s Cystic Fibrosis Therapy QR-010 Now Protected by U.S., European Patents Until 2033

Cystic Fibrosis-related ProQR Names New Therapy Development Chief

Top 10 Cystic Fibrosis Articles of 2016

Therapy Targeting CF Mutation Appears to Restore CFTR Gene in Homozygous Patients in Study

Data on Inhaled CF Therapy in Clinical Testing To Be Presented at NACFC 2016

Pin It on Pinterest